98%
921
2 minutes
20
Recently, a conceptually new mass analyzer was introduced by pairing a quadrupole Orbitrap mass spectrometer with an asymmetric track lossless (Astral™) analyzer. This system provides >200 Hz MS/MS scanning speed, high resolving power, sensitivity, and mass accuracy. Due to its speed, the instrument allows for a narrow-window data-independent acquisition (nDIA) strategy, representing a new technical milestone in peptide-centric proteomics. However, this new system may also be applied to other complex and clinically important proteomes, such as the human plasma N-glycoproteome. Here, we evaluate the Orbitrap Astral mass spectrometer for the in-depth analysis of the plasma N-glycoproteome and pioneer a dedicated nDIA workflow, termed "nGlycoDIA", on glycopeptide enriched and crude plasma. This strategy leads to the cumulative identification of over 3000 unique glycoPSMs derived from 181 glycoproteins in just 40 minutes and covers a dynamic range of 7 orders of magnitude for a glycopeptide enriched plasma sample. Notably, we detect several glycosylated cytokines that have reported plasma concentrations in the ng/L range. Furthermore, shortening the gradient to 10 min still allows for the detection of almost 1850 (95% CI [1840-1860]) unique glycoPSMs, indicating that high-throughput in-depth clinical plasma glycoproteomics may be within reach.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906852 | PMC |
http://dx.doi.org/10.1038/s41467-025-57916-1 | DOI Listing |
Talanta
July 2025
State Key Laboratory of Medical Proteomics, National Chromatographic R. & A. Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China; University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address:
Protein glycosylation is a critical post-translational modification, and knowledge of site-specific glycoforms is essential for developing biomarkers and therapeutic drugs. Although LC-MS/MS-based glycoproteomics strategies enable the identification of site-specific glycoforms at proteomics scale, their coverage is still low largely because of the poor glycopeptide enrichment performance. HILIC is thought to allow "unbiased" enrichment of intact glycopeptides, and it is broadly used to analyze the site-specific glycoforms at proteomics scale.
View Article and Find Full Text PDFAnal Chem
July 2025
School of Basic Medical Science, Anhui Medical University, Hefei 230032, China.
Plasma represents a highly valuable clinical sample for protein biomarker discovery, offering a comprehensive source of physiological and pathological information. N-glycosylation plays key roles in various biological processes and enhances the sensitivity of plasma protein biomarkers for disease diagnosis. Consequently, large-scale characterization of the plasma proteome and N-glycosylation patterns by mass spectrometry (MS) is crucial for identifying biomarkers but remains highly challenging due to three major difficulties.
View Article and Find Full Text PDFNat Commun
March 2025
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.
Recently, a conceptually new mass analyzer was introduced by pairing a quadrupole Orbitrap mass spectrometer with an asymmetric track lossless (Astral™) analyzer. This system provides >200 Hz MS/MS scanning speed, high resolving power, sensitivity, and mass accuracy. Due to its speed, the instrument allows for a narrow-window data-independent acquisition (nDIA) strategy, representing a new technical milestone in peptide-centric proteomics.
View Article and Find Full Text PDFJ Adv Res
July 2024
Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmeg
Introduction: The human plasma glycoproteome holds enormous potential to identify personalized biomarkers for diagnostics. Glycoproteomics has matured into a technology for plasma N-glycoproteome analysis but further evolution towards clinical applications depends on the clinical validity and understanding of protein- and site-specific glycosylation changes in disease.
Objectives: Here, we exploited the uniqueness of a patient cohort of genetic defects in well-defined glycosylation pathways to assess the clinical applicability of plasma N-glycoproteomics.
Talanta
July 2023
Shanghai Key Laboratory of Functional Materials Chemistry, School of Chemistry and Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China. Electronic address:
The development of facilely synthetic materials acts an essential role in glycoproteome analysis, especially for the highly efficient enrichment of N-linked glycopeptides. In this work, a facile and timesaving route was introduced in which COF served as a carrier and poly (ethylenimine) (PEI) and carrageenan (Carr) were successively coated on the surface via electrostatic interaction. The resultant COF@PEI@Carr showed remarkable performance in glycopeptide enrichment with high sensitivity (2 fmol μL), high selectivity (1:800, molar ratio of human serum IgG to BSA digests), large loading capacity (300 mg g), satisfactory recovery (102.
View Article and Find Full Text PDF